VistaGen Therapeutics Inc (VTGN)

[pinkslipjunkie]

VSTA It is also estimated that about one-third of all potential new drugs candidates fail in preclinical or clinical trials due to safety concerns. That is where Vistagen steps in and takes the shelved product and continues the research in getting around the the toxic reasons that put the drug on halt by the authorites in the first place. They believe focusing on discontinued drug candidates with positive efficacy data may give them a valuable “head start” in efforts to identify and develop new, proprietary drug rescue variants faster and less expensively than drug candidates discovered and developed using only conventional animal and in vitro cell culture testing.